Diffuse large B cell lymphoma of activated B cell type (ABC-DLBCL), a major cell-of-origin DLBCL subtype, is characterized by chronic active B cell receptor (BCR) signaling and NF-κB activation, which can be explained by activating mutations of the BCR signaling cascade in a minority of cases. We demonstrate that autonomous BCR signaling, akin to its essential pathogenetic role in chronic lymphocytic leukemia (CLL), can explain chronic active BCR signaling in ABC-DLBCL. 13 of 18 tested DLBCL-derived BCR, including 12 cases selected for expression of IgM, induced spontaneous calcium flux and increased phosphorylation of the BCR signaling cascade in murine triple knockout pre-B cells without antigenic stimulation or external BCR crosslinking. Autonomous BCR signaling was associated with IgM isotype, dependent on somatic BCR mutations and individual HCDR3 sequences, and largely restricted to non-GCB DLBCL. Autonomous BCR signaling represents a novel immunological oncogenic driver mechanism in DLBCL originating from individual BCR sequences and adds a new dimension to currently proposed genetics- and transcriptomics-based DLBCL classifications.

1st Department of Internal Medicine Hematology General University Hospital and 1st Faculty of Medicine Charles University Prague Czech Republic

BIOCEV 1st Faculty of Medicine Charles University Prague Czech Republic

Department of Hematology Leiden University Medical Center Leiden Netherlands

Department of Pathology Amsterdam University Medical Center Amsterdam Netherlands

Department of Pathology Leiden University Medical Center Leiden Netherlands

Institute of Immunology University of Ulm Ulm Germany

School of Medicine Universidad de Magallanes Punta Arenas Chile

See more in PubMed

Alaggio, R., Amador C., Anagnostopoulos I., Attygalle A.D., Araujo I.B.D., Berti E., Bhagat G., Borges A.M., Boyer D., Calaminici M., et al. . 2022. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms. Leukemia. 36:1720–1748. 10.1038/s41375-022-01620-2 PubMed DOI PMC

Alizadeh, A.A., Eisen M.B., Davis R.E., Ma C., Lossos I.S., Rosenwald A., Boldrick J.C., Sabet H., Tran T., Yu X., et al. . 2000. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 403:503–511. 10.1038/35000501 PubMed DOI

Allahyar, A., Pieterse M., Swennenhuis J., Los-de Vries G.T., Yilmaz M., Leguit R., Meijers R.W.J., van der Geize R., Vermaat J., Cleven A., et al. . 2021. Robust detection of translocations in lymphoma FFPE samples using targeted locus capture-based sequencing. Nat. Commun. 12:3361. 10.1038/s41467-021-23695-8 PubMed DOI PMC

Brault, L., Menter T., Obermann E.C., Knapp S., Thommen S., Schwaller J., and Tzankov A.. 2012. PIM kinases are progression markers and emerging therapeutic targets in diffuse large B-cell lymphoma. Br. J. Cancer. 107:491–500. 10.1038/bjc.2012.272 PubMed DOI PMC

Brochet, X., Lefranc M.P., and Giudicelli V.. 2008. IMGT/V-QUEST: The highly customized and integrated system for IG and TR standardized V-J and V-D-J sequence analysis. Nucleic Acids Res. 36:W503–W508. 10.1093/nar/gkn316 PubMed DOI PMC

Campo, E., Jaffe E.S., Cook J.R., Quintanilla-Martinez L., Swerdlow S.H., Anderson K.C., Brousset P., Cerroni L., de Leval L., Dirnhofer S., et al. . 2022. The international consensus classification of mature lymphoid neoplasms: A report from the clinical advisory committee. Blood. 140:1229–1253. 10.1182/blood.2022015851 PubMed DOI PMC

Chapuy, B., Stewart C., Dunford A.J., Kim J., Kamburov A., Redd R.A., Lawrence M.S., Roemer M.G.M., Li A.J., Ziepert M., et al. . 2018. Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes. Nat. Med. 24:679–690. 10.1038/s41591-018-0016-8 PubMed DOI PMC

Davis, R.E., Brown K.D., Siebenlist U., and Staudt L.M.. 2001. Constitutive nuclear factor kappaB activity is required for survival of activated B cell-like diffuse large B cell lymphoma cells. J. Exp. Med. 194:1861–1874. 10.1084/jem.194.12.1861 PubMed DOI PMC

Davis, R.E., Ngo V.N., Lenz G., Tolar P., Young R.M., Romesser P.B., Kohlhammer H., Lamy L., Zhao H., Yang Y., et al. . 2010. Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma. Nature. 463:88–92. 10.1038/nature08638 PubMed DOI PMC

Dühren-von Minden, M., Übelhart R., Schneider D., Wossning T., Bach M.P., Buchner M., Hofmann D., Surova E., Follo M., Köhler F., et al. . 2012. Chronic lymphocytic leukaemia is driven by antigen-independent cell-autonomous signalling. Nature. 489:309–312. 10.1038/nature11309 PubMed DOI

Ewels, P., Magnusson M., Lundin S., and Käller M.. 2016. MultiQC: Summarize analysis results for multiple tools and samples in a single report. Bioinformatics. 32:3047–3048. 10.1093/bioinformatics/btw354 PubMed DOI PMC

Garcia, M., Juhos S., Larsson M., Olason P.I., Martin M., Eisfeldt J., DiLorenzo S., Sandgren J., Díaz De Ståhl T., Ewels P., et al. . 2020. Sarek: A portable workflow for whole-genome sequencing analysis of germline and somatic variants. F1000 Res. 9:63. 10.12688/f1000research.16665.2 PubMed DOI PMC

Hans, C.P., Weisenburger D.D., Greiner T.C., Gascoyne R.D., Delabie J., Ott G., Müller-Hermelink H.K., Campo E., Braziel R.M., Jaffe E.S., et al. . 2004. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood. 103:275–282. 10.1182/blood-2003-05-1545 PubMed DOI

Havranek, O., Xu J., Köhrer S., Wang Z., Becker L., Comer J.M., Henderson J., Ma W., Man Chun Ma J., Westin J.R., et al. . 2017. Tonic B-cell receptor signaling in diffuse large B-cell lymphoma. Blood. 130:995–1006. 10.1182/blood-2016-10-747303 PubMed DOI PMC

Howlader, N., Mariotto A.B., Besson C., Suneja G., Robien K., Younes N., and Engels E.A.. 2017. Cancer-specific mortality, cure fraction, and noncancer causes of death among diffuse large B-cell lymphoma patients in the immunochemotherapy era. Cancer. 123:3326–3334. 10.1002/cncr.30739 PubMed DOI

Kanehisa, M., Furumichi M., Sato Y., Kawashima M., and Ishiguro-Watanabe M.. 2023. KEGG for taxonomy-based analysis of pathways and genomes. Nucleic Acids Res. 51:D587–D592. 10.1093/nar/gkac963 PubMed DOI PMC

Kim, S., Scheffler K., Halpern A.L., Bekritsky M.A., Noh E., Källberg M., Chen X., Kim Y., Beyter D., Krusche P., and Saunders C.T.. 2018. Strelka2: Fast and accurate calling of germline and somatic variants. Nat. Methods. 15:591–594. 10.1038/s41592-018-0051-x PubMed DOI

Koning, M.T., Kielbasa S.M., Boersma V., Buermans H.P., van der Zeeuw S.A., van Bergen C.A., Cleven A.H., Kluin P.M., Griffioen M., and Navarrete M.A.. 2017. ARTISAN PCR: Rapid identification of full-length immunoglobulin rearrangements without primer binding bias. Br. J. Haematol. 178:983–986. 10.1111/bjh.14180 PubMed DOI

Kuo, H.P., Ezell S.A., Hsieh S., Schweighofer K.J., Cheung L.W., Wu S., Apatira M., Sirisawad M., Eckert K., Liang Y., et al. . 2016. The role of PIM1 in the ibrutinib-resistant ABC subtype of diffuse large B-cell lymphoma. Am. J. Cancer Res. 6:2489–2501. PubMed PMC

Lenz, G., Davis R.E., Ngo V.N., Lam L., George T.C., Wright G.W., Dave S.S., Zhao H., Xu W., Rosenwald A., et al. . 2008. Oncogenic CARD11 mutations in human diffuse large B cell lymphoma. Science. 319:1676–1679. 10.1126/science.1153629 PubMed DOI

Li, H., and Durbin R.. 2009. Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics. 25:1754–1760. 10.1093/bioinformatics/btp324 PubMed DOI PMC

Maity, P.C., Bilal M., Koning M.T., Young M., van Bergen C.A.M., Renna V., Nicolò A., Datta M., Gentner-Göbel E., Barendse R.S., et al. . 2020. IGLV3-21*01 Is an inherited risk factor for CLL through the acquisition of a single-point mutation enabling autonomous BCR signaling. Proc. Natl. Acad. Sci. USA. 117:4320–4327. 10.1073/pnas.1913810117 PubMed DOI PMC

McKenna, A., Hanna M., Banks E., Sivachenko A., Cibulskis K., Kernytsky A., Garimella K., Altshuler D., Gabriel S., Daly M., and DePristo M.A.. 2010. The genome analysis toolkit: A MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res. 20:1297–1303. 10.1101/gr.107524.110 PubMed DOI PMC

McLaren, W., Pritchard B., Rios D., Chen Y., Flicek P., and Cunningham F.. 2010. Deriving the consequences of genomic variants with the Ensembl API and SNP effect predictor. Bioinformatics. 26:2069–2070. 10.1093/bioinformatics/btq330 PubMed DOI PMC

Meixlsperger, S., Köhler F., Wossning T., Reppel M., Müschen M., and Jumaa H.. 2007. Conventional light chains inhibit the autonomous signaling capacity of the B cell receptor. Immunity. 26:323–333. 10.1016/j.immuni.2007.01.012 PubMed DOI

Mendeville, M., Janssen J., Kim Y., van Dijk E., de Jong D., and Ylstra B.. 2022. A bioinformatics perspective on molecular classification of diffuse large B-cell lymphoma. Leukemia. 36:2177–2179. 10.1038/s41375-022-01670-6 PubMed DOI PMC

Minici, C., Gounari M., Übelhart R., Scarfò L., Dühren-von Minden M., Schneider D., Tasdogan A., Alkhatib A., Agathangelidis A., Ntoufa S., et al. . 2017. Distinct homotypic B-cell receptor interactions shape the outcome of chronic lymphocytic leukaemia. Nat. Commun. 8:15746. 10.1038/ncomms15746 PubMed DOI PMC

Naviaux, R.K., Costanzi E., Haas M., and Verma I.M.. 1996. The pCL vector system: Rapid production of helper-free, high-titer, recombinant retroviruses. J. Virol. 70:5701–5705. 10.1128/jvi.70.8.5701-5705.1996 PubMed DOI PMC

Ngo, V.N., Young R.M., Schmitz R., Jhavar S., Xiao W., Lim K.H., Kohlhammer H., Xu W., Yang Y., Zhao H., et al. . 2011. Oncogenically active MYD88 mutations in human lymphoma. Nature. 470:115–119. 10.1038/nature09671 PubMed DOI PMC

Phelan, J.D., Young R.M., Webster D.E., Roulland S., Wright G.W., Kasbekar M., Shaffer A.L. III, Ceribelli M., Wang J.Q., Schmitz R., et al. . 2018. A multiprotein supercomplex controlling oncogenic signalling in lymphoma. Nature. 560:387–391. 10.1038/s41586-018-0290-0 PubMed DOI PMC

Quinten, E., Sepúlveda-Yáñez J.H., Koning M.T., Eken J.A., Pfeifer D., Nteleah V., De Groen R.A.L., Saravia D.A., Knijnenburg J., Stuivenberg-Bleijswijk H.E., et al. . 2023. Autonomous B-cell receptor signaling and genetic aberrations in chronic lymphocytic leukemia-phenotype monoclonal B lymphocytosis in siblings of patients with chronic lymphocytic leukemia. Haematologica. 109:824–834. 10.3324/haematol.2022.282542 PubMed DOI PMC

Reddy, A., Zhang J., Davis N.S., Moffitt A.B., Love C.L., Waldrop A., Leppa S., Pasanen A., Meriranta L., Karjalainen-Lindsberg M.L., et al. . 2017. Genetic and functional drivers of diffuse large B Cell lymphoma. Cell. 171:481–494.e15. 10.1016/j.cell.2017.09.027 PubMed DOI PMC

Rosenwald, A., Wright G., Chan W.C., Connors J.M., Campo E., Fisher R.I., Gascoyne R.D., Muller-Hermelink H.K., Smeland E.B., Giltnane J.M., et al. . 2002. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N. Engl. J. Med. 346:1937–1947. 10.1056/NEJMoa012914 PubMed DOI

Ruminy, P., Etancelin P., Couronné L., Parmentier F., Rainville V., Mareschal S., Bohers E., Burgot C., Cornic M., Bertrand P., et al. . 2011. The isotype of the BCR as a surrogate for the GCB and ABC molecular subtypes in diffuse large B-cell lymphoma. Leukemia. 25:681–688. 10.1038/leu.2010.302 PubMed DOI

Schmitz, R., Wright G.W., Huang D.W., Johnson C.A., Phelan J.D., Wang J.Q., Roulland S., Kasbekar M., Young R.M., Shaffer A.L., et al. . 2018. Genetics and pathogenesis of diffuse large B-cell lymphoma. N. Engl. J. Med. 378:1396–1407. 10.1056/NEJMoa1801445 PubMed DOI PMC

Scott, D.W., Wright G.W., Williams P.M., Lih C.J., Walsh W., Jaffe E.S., Rosenwald A., Campo E., Chan W.C., Connors J.M., et al. . 2014. Determining cell-of-origin subtypes of diffuse large B-cell lymphoma using gene expression in formalin-fixed paraffin-embedded tissue. Blood. 123:1214–1217. 10.1182/blood-2013-11-536433 PubMed DOI PMC

Storch, B., Meixlsperger S., and Jumaa H.. 2007. The Ig-alpha ITAM is required for efficient differentiation but not proliferation of pre-B cells. Eur. J. Immunol. 37:252–260. 10.1002/eji.200636667 PubMed DOI

Thurner, L., Hartmann S., Bewarder M., Fadle N., Regitz E., Schormann C., Quiroga N., Kemele M., Klapper W., Rosenwald A., et al. . 2021. Identification of the atypically modified autoantigen Ars2 as the target of B-cell receptors from activated B-cell-type diffuse large B-cell lymphoma. Haematologica. 106:2224–2232. 10.3324/haematol.2019.241653 PubMed DOI PMC

Wilson, W.H., Wright G.W., Huang D.W., Hodkinson B., Balasubramanian S., Fan Y., Vermeulen J., Shreeve M., and Staudt L.M.. 2021. Effect of ibrutinib with R-CHOP chemotherapy in genetic subtypes of DLBCL. Cancer Cell 39:1643–1653.e1643. 10.1016/j.ccell.2021.10.006 PubMed DOI PMC

Wilson, W.H., Young R.M., Schmitz R., Yang Y., Pittaluga S., Wright G., Lih C.J., Williams P.M., Shaffer A.L., Gerecitano J., et al. . 2015. Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma. Nat. Med. 21:922–926. 10.1038/nm.3884 PubMed DOI PMC

Wright, G.W., Huang D.W., Phelan J.D., Coulibaly Z.A., Roulland S., Young R.M., Wang J.Q., Schmitz R., Morin R.D., Tang J., et al. . 2020. A probabilistic classification tool for genetic subtypes of diffuse large B cell lymphoma with therapeutic implications. Cancer Cell. 37:551–568.e14. 10.1016/j.ccell.2020.03.015 PubMed DOI PMC

Young, R.M., Wu T., Schmitz R., Dawood M., Xiao W., Phelan J.D., Xu W., Menard L., Meffre E., Chan W.C., et al. . 2015. Survival of human lymphoma cells requires B-cell receptor engagement by self-antigens. Proc. Natl. Acad. Sci. USA. 112:13447–13454. 10.1073/pnas.1514944112 PubMed DOI PMC